519 related articles for article (PubMed ID: 9286770)
1. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
5. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection?
el Gamel A; Keevil B; Rahman A; Campbell C; Deiraniya A; Yonan N
J Heart Lung Transplant; 1997 Mar; 16(3):268-74. PubMed ID: 9087869
[TBL] [Abstract][Full Text] [Related]
6. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
7. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
8. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
[TBL] [Abstract][Full Text] [Related]
9. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
10. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.
Sijpkens YW; Mallat MJ; Siegert CE; Zwinderman AH; Westendorp RG; de Fijter JW; van Es LA; Paul LC
Clin Nephrol; 2001 Feb; 55(2):149-55. PubMed ID: 11269679
[TBL] [Abstract][Full Text] [Related]
12. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
[TBL] [Abstract][Full Text] [Related]
14. [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole].
Videla C; Vega J; Borja H; Gatica A; Clavero R; Aldunate T
Rev Med Chil; 1997 Apr; 125(4):438-45. PubMed ID: 9460285
[TBL] [Abstract][Full Text] [Related]
15. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
[TBL] [Abstract][Full Text] [Related]
16. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
[TBL] [Abstract][Full Text] [Related]
17. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
Sharma A; Shekhar C; Heer M; Minz M
Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
[TBL] [Abstract][Full Text] [Related]
18. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
19. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
20. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
